Johnson & Johnson acquired AbioMed in 2022, and the FDA subsequently issued an early alert regarding device failure related to the acquisition.
4 reports, 4 independent
Updated Aug 3
Gone quiet
- Reports
- 4
- Developments
- 3
- Repetition
- 25%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Johnson & Johnson acquired AbioMed in 2022, and the FDA subsequently issued an early alert regarding device failure related to the acquisition.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA classified a defect in AbioMed's heart pump kits distributed across the US.1 source
JNJ operates the Abiomed heart pump business.1 source
J&J acquisition of AbioMed and FDA early alert regarding device failure.1 source
Keep exploring
The entities involved
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
AbioMed
medical devices company based in Danvers, Massachusetts, USA
Nothing else this week.
- FDA
Coverage
Newest first; wire copies grouped- medicaldaily.com
- bostonglobe.com
- yahoo.com
- MedTech DiveJ&J removes some Abiomed heart pump controllers from market This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newslette